Health
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
PRINCETON, N.J., March 29, 2026--BMS Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos in Adolescents with Symptomatic oHCM
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1497,"height":206,"url":"https://media.zenfs.com/en/business-wire.com/16ad61fd424ad3b672b81ed7034306d5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IL6gLKybnKw6YfAD1WNvCg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzMg--/https://media.zenfs.com/en/business-wire.com/16ad61fd424ad3b672b81ed7034306d5","width":960,"height":132},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Td_BEJvrWYJRZ0uYmlphcQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zMzA-/https://media.zenfs.com/en/business-wire.com/16ad61fd424ad3b672b81ed7034306d5","width":1200,"height":165}},"lazy":false},{"type":"text","content":"Trial met its primary endpoint, demonstrating clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28","length":177,"tagName":"p","attribs":{}},{"type":"text","content":"Results demonstrate the potential for Camzyos to be the first targeted pharmacological therapy for the treatment of oHCM in adolescents","length":135,"tagName":"p","attribs":{}},{"type":"text","content":"Safety profile of Camzyos in adolescents was similar to established profile in adults, with no new safety signals and no patients experiencing left ventricular ejection fraction (LVEF) of <50%","length":195,"tagName":"p","attribs":{}},{"type":"text","content":"PRINCETON, N.J., March 29, 2026--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced positive data from the Phase 3 SCOUT-HCM trial of Camzyos (mavacamten), the first study of a cardiac myosin inhibitor (CMI) in adolescents (ages 12 years to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The SCOUT-HCM trial met its primary endpoint, demonstrating a clinically meaningful and statistically significant reduction from baseline in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 with Camzyos versus placebo, with a significant least-squares (LS) mean difference (95% CI) at Week 28 of −48.0 (−67.7, −28.3) mm Hg; P < 0.0001.","length":691,"tagName":"p"},{"type":"text","content":"Additionally, Camzyos showed meaningful improvement over placebo in multiple secondary endpoints at 28 weeks, and similar safety findings were observed in the Camzyos and placebo groups...